A meta-analysis of the efficacy of omega-3 supplementation in people with NAFLD/NASH during a median duration of 6 months showed that omega-3 polyunsaturated fatty acid supplementation reduced liver fat measured by ultrasound, magnetic resonance imaging, or biopsy and improved liver enzymes (AST and ALT) [88]. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.